Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

NCT05218759 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Anlotinib

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]